Performance of OncoE6 cervical test with collection methods enabling self-sampling by Krings, Amrei et al.
TECHNICAL ADVANCE Open Access
Performance of OncoE6 cervical test with
collection methods enabling self-sampling
Amrei Krings1, Anna M. Dückelmann1, Lutz Moser2, Johannes Gollrad2, Maarten Wiegerinck3,
Johannes Schweizer4 and Andreas M. Kaufmann1,5*
Abstract
Background: The paradigm shift from cytological screening to Human Papillomavirus (HPV)-based screening for
cervical cancer allows the introduction of new technologies in sample collection and diagnostics. The OncoE6™
Cervical Test (OncoE6 Test) is a rapid, easy-to-use lateral flow method detecting HPV16/18 E6 oncoproteins that has
proven to detect high-grade cervical lesions with high specificity. If compatible with self-collection samples, this
technology might allow for decentralized screening of hard-to-reach populations.
Methods: For technical validation, cervicovaginal lavages were collected from 20 patients with confirmed HPV16+
or HPV18+ invasive cervical cancer. Cervical smears were collected by polyester-tipped swabs and cytobrushes. All
samples were applied to the OncoE6 Test and cytobrush samples additionally genotyped.
Results: Lavage, swab, and cytobrush revealed concordant outcome in 18/20 samples. HPV types corresponded
with the HPV genotyping by GP5+/6+ PCR analyses. Due to a rare mutation found in the E6 antibody binding site
one sample was not detected, another sample had very low cellularity.
Conclusions: Overall, vaginal lavages are technically adequate for the OncoE6 Test. Combining self-sampling with
oncoprotein rapid testing to detect women with highest risk for severe dysplasia or cancer may allow for secondary
cancer prevention in settings where other screening modalities were unsuccessful to date.
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Background
Despite successes in reduction of cervical cancer related
mortality by the introduction of screening programs in
developed regions, the worldwide cervical cancer inci-
dence remains high, especially in developing countries.
The World Health Organization (WHO) estimates more
than 550.000 new cases annually [1]. Cervical cancer is a
relatively rare consequence of high-risk human papillo-
maviruses (hr-HPV) infection and the WHO has classi-
fied 12 h-HPV genotypes detectable in > 95% of invasive
cervical squamous carcinoma [2, 3]. While hr-HPV in-
fection has a relatively high prevalence of 5–20% in
many regions, > 20% can be observed in regions of high
HIV prevalence and in women < 25 years old [1]. The
HPV types 16 and 18 account for more than 70% of cer-
vical cancers [4].
The association of cervical cancer with hr-HPV (virtu-
ally 100% of cervical squamous cell carcinomas are
caused by HPV) has motivated the development of mo-
lecular screening tests detecting presence of HPV, and
WHO recommends the introduction of such screening
tools [5]. Generally, HPV tests are characterized by high
sensitivity but suffer from low specificity for true disease
due to many infections resolving spontaneously or not
leading to cervical cancer (HPV infection rarely result in
cervical cancer) [6].
A necessary pathogenic event during cervical cancer
carcinogenesis is the upregulation of HPV encoded
oncoprotein expression. The maintained expression of
HPV oncoproteins E6 and E7 is a prerequisite for inva-
sive cervical cancer to develop, while levels of the E6
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and E7 oncoproteins and the corresponding mRNAs are
at a very low level in non-transforming HPV infections
and low grade dysplasia [7, 8]. These findings motivated
the development of the OncoE6™ Cervical Test (OncoE6
Test), a technology directly detecting elevated levels of
the E6 oncoprotein of HPV types 16 and 18 [9]. The
OncoE6 Test relies on genotype-specific mouse mono-
clonal antibodies (mAbs) to HPV 16 E6 and HPV 18 E6
oncoproteins; these mAbs are used in the format of a
lateral flow assay (strip test) of high robustness [9].
The OncoE6 lateral flow assay was validated in numer-
ous clinical studies, and initially only physician collected
specimens were used in those studies. For example, in a
large (~ 7500 subjects enrolled) screening study con-
ducted in several rural areas in China, the OncoE6 Test
had the highest specificity for detection of CIN3 and
cervical cancer among all tests involved (compared to
careHPV and VIA) at 98.9%; the sensitivity of the
OncoE6 Test for CIN3+ was 53.5% for all lesions de-
tected and 70.3% when stratified for lesions positive for
the HPV types 16/18/45. In this study, the OncoE6 Test
had by far the highest positive predictive value (PPV) for
CIN3 of 40.8%, while the PPV of HPV testing and VIA
was < 10%; the negative predictive value was 99.4% [10].
In low resource settings, tests with high specificity that
are also compatible with self-sampling would be advan-
tageous as they facilitate cervical cancer screening of
women in remote locations and of women who are hesi-
tant to present to physicians, while reducing unnecessary
referrals [11, 12]. We therefore investigated compatibility
of the OncoE6 Test with specimens collected by self-
sampling. We chose to use cervicovaginal lavages that
had previously been shown to be compatible with HPV
genotyping [11, 13, 14]; we compared OncoE6 Test per-
formance on self-sampling device collected specimens
with physician collected swabs and the cervical brush
samples. For this truly technical comparison we sampled
from women with histologically confirmed cervical can-
cers caused by HPV genotypes 16 or 18, and we tested
the different sampling methods with regard to the Onco
E6 Test, comparing the results to the molecular HPV
genotyping performed on the cytobrush samples.
Methods
Patient and samples
Patients were eligible for the study if they presented with
HPV 16 or 18 positive invasive cervical cancer, if they
have not had a history of conisation or other treatments
for cervical cancer, if they were not pregnant and gave
their written consent to participate in the study. Ethical
approval for this study was granted by Charité Universi-
tätsmedizin Berlin ethical review board (EA1/168/13).
From each patient three different samples were col-
lected in the following order: a vaginal lavage sample (1)
taken with the self-sampling device Delphi Screener
(Rovers Medical Devices, Oss, Netherlands), a dry sample
(2) collected with a sterile polyester tipped swab (#25–806
1PD, Puritan Medical Products) and a cytobrush sample
(3) that was applied to PreservCyt storage media (Thin-
Prep, Hologic Inc., Marlborough, MA, USA). Before the
swab and cytobrush sampling, a speculum was inserted
and these two samples were collected from the cervix or,
if visible, directly by touching the tumour. All three sam-
ples were collected by a physician. The samples were
stored at − 20 °C until processing.
OncoE6 test
All three samples were applied to the OncoE6™ Cervical
Test (Arbor Vita Corporation, Fremont, CA, USA) fol-
lowing the manufacturer’s instructions. The lavage sam-
ple (1) was centrifuged and the whole cell pellet re-
suspended in lysis buffer. The entire lavage sample was
used for the OncoE6 Test to assure highest yield of cells
and hence the best possible results. The swab sample (2)
, was transferred into a tube for lysis without any further
preparation, according to the standard protocol provided
for the OncoE6 Test. Of the cytobrush sample (3) in
PreservCyt storage media, 5 out of 20 ml of cell suspen-
sion were centrifuged and the cell pellet was re-
suspended in lysis buffer and subsequently applied to
the OncoE6 Test. The protocol provided by Arbor Vita
Corporation for PreservCyt samples recommends as lit-
tle as 2 ml cell suspension. We used 5 ml to assure the
expected amount of cells would be sufficient.
The OncoE6 Test results for all three sample types
were compared to the HPV genotyping outcome, and
subsequently the lavage and cytobrush sample results
were compared to the swab-based test result.
HPV DNA-based testing
HPV genotyping was performed using the cytobrush
sample (3) kept in storage media; 1 ml of this cell sus-
pension was used. DNA was extracted using the QIAmp
DNA mini kit (Qiagen, Hilden, Germany) and following
the manufacturer’s instructions. The extracted DNA was
submitted to genotyping using the BSGP5+/6+ PCR ap-
proach followed by a Luminex-based readout [15]. The
outcome constituted the reference result for HPV geno-
type status of the patient.
Additional analysis
For all cytobrush samples DNA concentrations were
measured using the NanoDrop 2000 (Thermo Scientific,
Wilmington, USA) device. It was not possible to meas-
ure DNA concentration from the lavage and swab sam-
ple, as those were fully used for the OncoE6 test.
One sample (#5) was applied to DNA sequencing of
the E6/E7 gene region in the HPV genome (Eurofins
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Genomics GmbH, Ebersberg, Germany). Primers encom-
passed the E6 region of HPV 16 (NCBI accession #: NC_




Complete sample sets (a “sample set” consists of: lavage,
swab, and cytobrush) were obtained from 20 patients
with histologically confirmed invasive cervical cancers;
subjects had been pre-selected for infections with HPV
types 16 and/or HPV 18; the patients presented at the
Clinic for Gynaecology or Radiology, Charité University
Hospital in Berlin for treatment. The median patient age
was 45 years, ranging from 26 years to 64 years. The pa-
tients came to the clinic for surgery and/or radiochemo-
therapy, at which occasion the samples were collected.
None of the patients had previously received treatment
for cervical cancer (some patients had to be excluded
from the analysis because their medical record revealed
prior treatment for cervical cancer).
HPV genotyping results
The genotyping results obtained at the time of sample
collection confirmed that 15 out of the 20 cervical can-
cer patients were positive for HPV 16 and the remaining
5 patients for HPV 18. Three patients each were also
positive for additional high-risk HPV types albeit at
lower virus load or with a borderline positive result.
None was positive for HPV 16 and HPV 18
simultaneously.
OncoE6 test results
The outcome of the OncoE6 Test for lavage, swab and
cytobrush samples was highly consistent (see Table 1).
E6 oncoprotein positive types by the OncoE6 Test also
corresponded to the HPV types 16 or 18 as detected by
BSGP5+/6+ PCR genotyping from the cytobrush refer-
ence sample. One sample (#14) had a very faint double
positive result for HPV 18 and 16 (HPV16 weak) in the
lavage sample, and two sample sets showed partially dis-
cordant results, warranting further examination as de-
scribed below.
Verification of discordant assay results
Sample set # 5 (see Table 1) repeatedly tested negative
for the OncoE6 Test with all three sample types (Delphi
Screener lavage, Swab, and Cytobrush), while the
L1-based BSGP5+/6+ PCR MPG HPV typing clearly in-
dicated presence of HPV 16. This sample was therefore
examined for mutations in the HPV 16 E6 DNA se-
quence, hypothesizing that such mutations might alter
the E6 oncoprotein binding to the anti-E6 specific
monoclonal antibodies (mAb) applied in the OncoE6
Test. The primers chosen encompassed the sequence
coding for the epitope recognized by the respective mAb
included in the OncoE6 Test. The sequence analysis re-
vealed a single nucleotide exchange (point mutation) at
N120 from adenine to guanine, resulting in an altered
E6 protein amino acid sequence in position 6 (Gln to
Arg). Another point mutation was detected at N350
from thymine to guanine, coding for position 90 of the
E6 protein amino acid sequence and resulting in a
change from Leu to Val. We hypothesize that the muta-
tion in position 6 reduced binding strength of the epi-
tope to the anti-E6 mAb used in the OncoE6 Test, thus
resulting in a false negative outcome.
The second discordant sample set (# 15), tested nega-
tive for HPV 16 with the Delphi Screener lavage sample
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and the cytobrush sample, but tested positive for HPV
16 from the swab sample (the latter in concordance with
the control genotyping). Possible reasons for these false
negative results could be insufficient cellularity in the re-
spective samples. To judge cellularity of the false nega-
tive sample we compared DNA content of the cytobrush
samples by NanoDrop measurements as an indirect
measure of possible cellularity problems. A low DNA
concentration was seen in the cytobrush collected sam-
ple with only 6 ng/μl while positive samples had a mean
content of 51.9 ng/μl (range 2.8 to 208.9). Sample # 9
and #18 had low DNA concentrations in the cytobrush
samples as well with 2.8 and 6 ng/μl, respectively, while
the OncoE6 results for these samples were positive.
Based on these test results the sensitivity to detect
HPV 16 or 18 positive cervical cancers by the OncoE6
Test with the Delphi Screener lavage and the cytobrush
sample in PreservCyt media was determined at 90% and
for the swab sample at 95%. After exclusion of sample
set #5 due to the E6 epitope mutation described above,
sensitivity can be adjusted to 95%. For the swab sample,
sensitivity was 100% (Table 2). Specificity cannot be cal-
culated, as none HPV 16 or 18 negative patients were in-
cluded in this initial study enrolment.
Discussion
The shift from cytology-based cervical cancer screening
to molecular-based screening opens the path for self-
sampling in conjunction with nucleic acid based HPV
tests and potentially also with HPV oncoprotein tests
[12]. The Delphi Screener is a self-sampling device that
is easy to use, well accepted by the users and that results
in sufficient material for HPV DNA testing [11, 14, 16].
This device, however, had never been validated in con-
junction with the OncoE6 Test, for which most studies
up to date were done using swab samples. Here, we per-
formed a technical validation study using the Delphi
screener in conjunction with the OncoE6 Test. For this,
we selected 20 patients with HPV 16 or HPV 18 positive
histology confirmed cervical cancers. Three different
sample types were obtained (Delphi lavage, swab, cyto-
brush) and performance of OncoE6 Test performance
was determined for these sample types, using histology
as the gold standard for pathology and the L1-based
BSGP5+/6+ PCR Multiplexed Genotyping with Luminex
readout as the standard for HPV status. The result sug-
gests high sensitivity for detection of cervical cancer by
the OncoE6 Test using all three sample types, the self-
sampling device generated specimens, the swab samples
and also the cytobrush liquid media-based samples.
Two of the 20 samples revealed discordant outcome
resulting in a sensitivity of 90% for the self-sampling de-
vice, however, this may not be applicable with regard to
cervical cancer screening by the OncoE6 Test in a popu-
lation wide setting, as substantiated by the outcome of
our further analysis.
One sample set (# 5) was negative in OncoE6 testing
for all three sampling methods, despite a strong positive
signal for HPV 16 in the L1-based genotyping assay. Se-
quencing of the E6-specific epitope coding gene segment
revealed a non-silent mutation within the E6 gene se-
quence, suggesting that the resulting epitope has re-
duced binding strength to the anti E6 mAb used in the
OncoE6 Test. Review of the literature for description of
E6 specific mutations revealed several studies from vari-
ous countries (e.g. Congo, Morocco, Romania, China).
The mutation we found in our sample set # 5, however,
was not described in any of the studies [17–25]. We
therefore conclude that this mutation represents a very
low frequency mutation and will thus not influence the
clinical performance of the OncoE6 Test in the general
population, since it is highly unlikely to find this same
mutation in relevant numbers elsewhere. Future analyses
of discrepant screening by OncoE6 Test results should
include interrogation for this mutation.
A major objective of our study was to assess whether
or not the Delphi Screener lavage sample self-sampling
device is in principle technically compatible with the
OncoE6 Test; we therefore focused on samples from
HPV 16/18 positive histologically confirmed cervical
cancer patients. Excluding the one inadequate sample
from our analysis, sensitivity for the self-sampling device
among cervical cancer patients selected for this technical
validation is at 95% (18/19 samples correctly detected)
for the detection of HPV 16 or 18 induced cervical can-
cers using the Delphi Screener lavage. It can be expected
that such very rare mutations do not reduce sensitivity
of the OncoE6 test in population-based screening
significantly.
The second sample set (# 15) resulting in discrepant
outcome showed negative results for the lavage sample
as well as the cytobrush sample with the OncoE6 Test,
while the result for the swab sample was positive for E6
oncoprotein. It was noticeable that HPV genotyping per-
formed from the cytobrush sample in PreservCyt media
showed very low signal strength with the semi-
quantitative BSGP5+/6+ PCR with Luminex readout,
suggesting the sample was very low on HPV positive
cells. To investigate further, we measured the DNA con-
centration in the cytobrush samples and this sample had
a DNA concentration of only 6 ng/μl. Potentially, only
few cancer cells were collected, or the tumour was not
Table 2 OncoE6 Test Positivity rates by sampling method
Samples tested (n=19a) Lavage Swab Cytobrush
OncoE6 pos. 18 (95%) 19 (100%) 18 (95%)
OncoE6 neg. 1 (5%) 0 (0%) 1 (5%)
a One sample excluded due to E6 epitope mutation
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directly accessible for sample collection, resulting in
negative test results for the cytobrush and the lavage
sample. It is possible, therefore, that the number of E6
expressing cells was too low, thus resulting in a negative
OncoE6 Test. In contrast, sample #9 and #18 showed a
low DNA concentration, suggesting low cellularity of the
sample, but in this case it did not seem to have an im-
pact on the genotyping results, which presented positive
with high signal strength. As hypothesized previously,
self-collected samples bear the risk of not containing
enough biological material [26]. Also the location of the
lesion, its size, viral load, and smear quality can vary be-
tween patients. Data from other studies indicate that
even lesions that are too small to be seen in Colposcopy
can yield enough E6 protein to be detected in the
OncoE6 test [27]. In addition, samples collected with
such devices are not specific to the lesion/tumour or the
cervix but are cervico-vaginal samples that can contain
various types of cells. This might affect the use of such
samples in the OncoE6 Test. Since it is difficult to assess
how many “correct” cells are collected with self-
sampling devices, the impact on sensitivity and specifi-
city of the test needs to be investigated further in
population-based screening studies.
Weighing the advantages of wider population benefits
due to extended screening possibilities against the draw-
backs of a potentially limited sensitivity, we conclude
that the Delphi Screener-based lavage sampling repre-
sents a very promising approach in conjunction with E6
oncoprotein testing. The undisputed advantages in ease
of use and acceptance by the use of self-sampling in
conjunction with the high positive predictive value and
high specificity of disease detection, as demonstrated for
the OncoE6 Test in population-based sampling studies
[10], represent important features for effective cervical
cancer screening. Elsewhere, the capacity of the OncoE6
Test to stratify risk and to predict >CIN3 at a time point
where lesions are not yet visible has been described. In
the study of Zhang et al., it was found that women who
tested positive for E6 oncoprotein had a ten year cumu-
lative incidence rate of 53.0% for >CIN3 [27]. This could
potentially reduce over-referral and allow early and ef-
fective treatment of women at high risk, which is of
great importance in low-middle income countries
(LMICs) and in difficult to access populations.
Our study outcome warrants further investigation in
larger population-based studies. The focus of our inves-
tigation was foremost to prove the technical feasibility of
this approach, and we therefore concentrated on pa-
tients with invasive disease positive for HPV 16 or 18.
This does not allow any conclusion on the sensitivity
and specificity to be found among women with CIN2 or
CIN3 lesions. Future studies should include a more typ-
ical screening population and thus allow determination
of the clinical specificity of self-collection in conjunction
with the OncoE6 Test and assess its usability as a
screening test for early detection of lesions. The lower
specificity of self-sampling devices has already been
mentioned by Arbyn et al. [13] and should also be fur-
ther investigated for this combination of self-sampling
device and OncoE6 test.
Using self-sampling devices and E6 oncoprotein test-
ing for cervical cancer screening would allow highly ef-
fective selection of women with a high-risk for cervical
lesions. Reaching out by self-sampling to women who
normally may not benefit from the screening activities
or even avoid participation due to cultural barriers could
enhance success of preventive strategies [28]. This is es-
pecially useful for decentralized cervical cancer screen-
ing in resource-constrained settings. A self-collection of
lavage samples with the Delphi Screener allows sample
collection without a doctor’s visit. Once a positive test
result is obtained, the patient would be called to be re-
ferred to triage and treatment. Such approaches have
been shown to motivate patients to consult a gynaecolo-
gist [28].
Conclusions
This technical validation shows promising results for E6
oncoprotein testing from lavage samples obtained by a
self-collection device, from swab samples and from cyto-
brush samples, yet further studies are be needed to in-
vestigate the feasibility in the general population. The
feasibility of self-sampling in conjunction with the highly
specific oncoprotein-based test may constitute an im-
portant element of cervical cancer secondary prevention
in regions and resource constrained settings that could
not be served in the past.
Abbreviations
HPV: Human Papillomavirus; Hr-HPV: high-risk human papillomavirus;
LMICs: low-middle income countries; mAbs: monoclonal antibodies; OncoE6
test: OncoE6™ Cervical Test; PPV: positive predictive value; WHO: World
Health Organization
Acknowledgements
We would like to acknowledge Mrs. Ursula Schiller for her technical support
in analysing the samples.
Funding
This research did not receive any specific grant from funding agencies
in the public, commercial, or nor-for-profit sectors. The sampling devices
and oncoprotein tests were donated by Delphi Bioscience and by Arbor
Vita Corporation; the donors restrained themselves from taking influence
on the study design, analysis or interpretation of the results; in this regard, any
advice from the companies only occurred upon invitation by the study principal
investigator. We acknowledge support from the German Research Foundation
(DFG) and the Open Access Publication Fund of Charité – Universitätsmedizin
Berlin.
Availability of data and materials
All data generated or analysed during this study are included in this
published article.
Krings et al. BMC Women's Health  (2018) 18:68 Page 5 of 7
Authors’ contributions
AK and AMK designed the study protocol. MW and JS instructed on the usage
of the self-sampling device and the OncoE6 Cervical Test usage with the various
sample types used. AMD, LM and JG collected samples and evaluated clinical
data from women presenting with cervical cancer at the Department of
Gynaecology and Radiology, with AK performing the experiments and
were therefore all responsible for data acquisition. AK analysed the data
and interpreted it together with AMK. AK drafted the first manuscript. All
authors gave input or revised the final manuscript critically. All authors
read and approved the final manuscript, and take public responsibility
for its content.
Ethics approval and consent to participate
Ethical approval for this study was granted by Charité Universitätsmedizin
Berlin ethical review board (EA1/168/13) and patients gave their written
consent to participate in the study.
Competing interests
AK The authors declare that they have no competing interests.
AMD The authors declare that they have no competing interests.
LM The authors declare that they have no competing interests.
JG The authors declare that they have no competing interests.
MW is founder of Mysample Device Diagnostics B.V. and former of Delphi
Bioscience, the company producing the self-sampling device Delphi Screener
before acquisition by Rovers Medical Devices.
JS is an employee and shareholder at Arbor Vita Corporation, producing the
OncoE6 Cervical Test.
AMK The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Clinic for Gynecology CCM/CBF, Charité-Universitätsmedizin Berlin,
corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin,
and Berlin Institute of Health, Berlin, Germany. 2Department of
Radiooncology, CBF, Charité-Universitätsmedizin Berlin, corporate member of
Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of
Health, Berlin, Germany. 3Mysample Device Diagnostics B.V, Amsterdam, The
Netherlands. 4Arbor Vita Corporation, Fremont, CA, USA. 5Gynäkologische
Tumorimmunologie, Charité-Universitätsmedizin Berlin, Campus Benjamin
Franklin, Hindenburgdamm 30 Room # 4503, 12200 Berlin, Germany.
Received: 12 January 2018 Accepted: 1 May 2018
References
1. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D,
Muñoz J, Bosch F, de Sanjosé S. ICO/IARC Information Centre on HPV and
Cancer (HPV Information Centre). Human Papillomavirus and Related
Diseases in the World. Summary Report 27 July 2017. http://www.hpvcentre.
net/statistics/reports/XWX.pdf. Accessed 13 May 2018.
2. International Agency for Research on Cancer. Biological agents. A review of
human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100B.
3. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV,
Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary
cause of invasive cervical cancer worldwide. J Pathol. 1999;189(1):12–9.
4. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B,
Tous S, Felix A, Bravo LE, Shin HR, et al. Human papillomavirus genotype
attribution in invasive cervical cancer: a retrospective cross-sectional
worldwide study. Lancet Oncol. 2010;11(11):1048–56.
5. World Health Organization. Guidelines for screening and treatment of
precancerous lesions for cervical cancer prevention. Geneva: World Health
Organization; 2013. https://www.ncbi.nlm.nih.gov/books/NBK195239/.
Accessed 15 May 2018.
6. Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL,
Stanley M, Arbyn M, Poljak M, et al. Comprehensive control of human
papillomavirus infections and related diseases. Vaccine. 2013;31(Suppl 7):H1–31.
7. Jiang B, Xue M. Correlation of E6 and E7 levels in high-risk HPV16 type
cervical lesions with CCL20 and Langerhans cells. Genet Mol Res. 2015;
14(3):10473–81.
8. Schmitt M, Dalstein V, Waterboer T, Clavel C, Gissmann L, Pawlita M. The
HPV16 transcriptome in cervical lesions of different grades. Mol Cell Probes.
2011;25(5–6):260–5.
9. Schweizer J, Lu PS, Mahoney CW, Berard-Bergery M, Ho M, Ramasamy V,
Silver JE, Bisht A, Labiad Y, Peck RB, et al. Feasibility study of a human
papillomavirus E6 oncoprotein test for diagnosis of cervical precancer and
cancer. J Clin Microbiol. 2010;48(12):4646–8.
10. Zhao FH, Jeronimo J, Qiao YL, Schweizer J, Chen W, Valdez M, Lu P, Zhang
X, Kang LN, Bansil P, et al. An evaluation of novel, lower-cost molecular
screening tests for human papillomavirus in rural China. Cancer Prev Res
(Phila). 2013;6(9):938–48.
11. Bosgraaf RP, Verhoef VM, Massuger LF, Siebers AG, Bulten J, de Kuyper-de
Ridder GM, Meijer CJ, Snijders PJ, Heideman DA, IntHout J, et al.
Comparative performance of novel self-sampling methods in detecting
high-risk human papillomavirus in 30,130 women not attending cervical
screening. Int J Cancer. 2015;136(3):646–55.
12. Gravitt PE, Belinson JL, Salmeron J, Shah KV. Looking ahead: a case for
human papillomavirus testing of self-sampled vaginal specimens as a
cervical cancer screening strategy. Int J Cancer. 2011;129(3):517–27.
13. Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S,
Bellisario C, Banzi R, Zhao FH, et al. Accuracy of human papillomavirus
testing on self-collected versus clinician-collected samples: a meta-analysis.
Lancet Oncol. 2014;15(2):172–83.
14. Delere Y, Schuster M, Vartazarowa E, Hansel T, Hagemann I, Borchardt S,
Perlitz H, Schneider A, Reiter S, Kaufmann AM. Cervicovaginal self-sampling
is a reliable method for determination of prevalence of human
papillomavirus genotypes in women aged 20 to 30 years. J Clin Microbiol.
2011;49(10):3519–22.
15. Schmitt M, Dondog B, Waterboer T, Pawlita M. Homogeneous amplification
of genital human alpha papillomaviruses by PCR using novel broad-
spectrum GP5+ and GP6+ primers. J Clin Microbiol. 2008;46(3):1050–9.
16. Delere Y, Remschmidt C, Leuschner J, Schuster M, Fesenfeld M, Schneider A,
Wichmann O, Kaufmann AM. Human papillomavirus prevalence and
probable first effects of vaccination in 20 to 25 year-old women in
Germany: a population-based cross-sectional study via home-based self-
sampling. BMC Infect Dis. 2014;14:87.
17. Boumba LM, Assoumou SZ, Hilali L, Mambou JV, Moukassa D, Ennaji MM.
Genetic variability in E6 and E7 oncogenes of human papillomavirus type
16 from Congolese cervical cancer isolates. Infect Agent Cancer. 2015;10:15.
18. Burk RD, Harari A, Chen Z. Human papillomavirus genome variants. Virology.
2013;445(1–2):232–43.
19. Hildesheim A, Schiffman M, Bromley C, Wacholder S, Herrero R,
Rodriguez A, Bratti MC, Sherman ME, Scarpidis U, Lin QQ, et al. Human
papillomavirus type 16 variants and risk of cervical cancer. J Natl
Cancer Inst. 2001;93(4):315–8.
20. Huertas-Salgado A, Martin-Gamez DC, Moreno P, Murillo R, Bravo MM, Villa
L, Molano M. E6 molecular variants of human papillomavirus (HPV) type 16:
an updated and unified criterion for clustering and nomenclature. Virology.
2011;410(1):201–15.
21. Plesa A, Anton G, Iancu IV, Diaconu CC, Huica I, Stanescu AD, Socolov D,
Nistor E, Popa E, Stoian M, et al. Molecular variants of human papilloma
virus 16 E2, E4, E5, E6 and E7 genes associated with cervical neoplasia in
Romanian patients. Arch Virol. 2014;159(12):3305–20.
22. Qmichou Z, Khyatti M, Berraho M, Ennaji MM, Benbacer L, Nejjari C,
Benjaafar N, Benider A, Attaleb M, El Mzibri M. Analysis of mutations in the
E6 oncogene of human papillomavirus 16 in cervical cancer isolates from
Moroccan women. BMC Infect Dis. 2013;13:378.
23. Yamada T, Manos MM, Peto J, Greer CE, Munoz N, Bosch FX, Wheeler CM.
Human papillomavirus type 16 sequence variation in cervical cancers: a
worldwide perspective. J Virol. 1997;71(3):2463–72.
24. Yang L, Yang H, Wu K, Shi X, Ma S, Sun Q. Prevalence of HPV and variation
of HPV 16/HPV 18 E6/E7 genes in cervical cancer in women in South West
China. J Med Virol. 2014;86(11):1926–36.
25. Yang Y, Ren J, Zhang Q. Distribution of human papilloma virus type 16 E6/
E7 gene mutation in cervical precancer or cancer: a case control study in
Guizhou Province, China. J Med Virol. 2016;88(2):345–50.
26. Belinson JL, Hu S, Niyazi M, Pretorius RG, Wang H, Wen C, Smith JS, Li J,
Taddeo FJ, Burchette RJ, et al. Prevalence of type-specific human
Krings et al. BMC Women's Health  (2018) 18:68 Page 6 of 7
papillomavirus in endocervical, upper and lower vaginal, perineal and
vaginal self-collected specimens: implications for vaginal self-collection. Int J
Cancer. 2010;127(5):1151–7.
27. Zhang Q, Dong L, Hu S, Feng R, Zhang X, Pan Q, Ma J, Zhang L, Zhao X,
Sankaranarayanan R, et al. Risk stratification and long-term risk prediction of
E6 oncoprotein in a prospective screening cohort in China. Int J Cancer.
2017;141(6):1110–9.
28. Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M,
Barletta P, Laudi R, Orellana L, team EMAS. Effect of self-collection of HPV
DNA offered by community health workers at home visits on uptake of
screening for cervical cancer (the EMA study): a population-based cluster-
randomised trial. Lancet Glob Health. 2015;3(2):e85–94.
Krings et al. BMC Women's Health  (2018) 18:68 Page 7 of 7
